Clinical effects on disease severity and quality of life of myasthenia gravis patients based on telemedical treatment with point-of-care diagnostics in the integrated myasthenia center (iMZ) - a pilot study - MyaLink

Charité Campus Charité Mitte0 个研究点目标入组 45 人开始时间: 2022年8月19日最近更新: 2024年8月19日

适应症

试验速览

暂无简介。

•Participants must suffer from myasthenia gravis (ICD-10: G70.0), the diagnosis must have existed for at least 6 months
•Participants must be treated in the iMZ of the Charité Berlin
•Participants must communicate in German without an interpreter
•Age of majority, minimum age 18 years

•Organic brain diseases (ICD-10: F0x)
•Intellectual disability (ICD-10: F7x)
•Physical illnesses with limitations that make regular participation and data entry via a smartphone impossible
•Inability to conduct the study and understand the risks involved
•Patients with a somatic, psychiatric or neurological disease or treatment that can impair cognitive functions or are not stable under drug treatment and could have an impact on the parameters to be examined.
•Patients who do not have a smartphone or tablet (operating system requirement at least iOS 14 or Android 9).

发起方

Charité Campus Charité Mitte